Business Context and Reporting Period
This Form 8-K Current Report was filed by Propanc Biopharma, Inc. on August 12, 2022 (with a signature date of August 18, 2022). The filing discloses the entry into material definitive agreements involving the issuance of convertible redeemable notes to raise capital for general working capital purposes.
Key Financial Metrics and Debt Obligations
The filing details two distinct debt instruments issued to private investors:
- GS Capital Partners, LLC Note:
- Principal Amount: $93,000
- Original Issue Discount: $5,000
- Net Proceeds: $88,000
- Interest Rate: 8% per annum (payable in cash or shares)
- Maturity Date: August 12, 2023
- Legal Fees Paid: $5,500
- ONE44 Capital LLC Note:
- Principal Amount: $110,000
- Original Issue Discount: $10,000
- Net Proceeds: $100,000
- Interest Rate: 10% per annum (payable in cash or shares)
- Maturity Date: August 15, 2023
- Legal Fees to be Paid: $5,500
The filing text does not provide clear values for total revenue, operating profit, cash flow from operations, or existing debt levels outside of these specific new obligations.
Material Changes and Terms
The primary material change is the incurrence of new debt obligations totaling $203,000 in principal. Key terms include:
- Conversion Rights:
- GS Capital: Convertible at a fixed price of $0.0028 per share, dropping to $0.0013 if the stock trades below $0.002 for five consecutive days. In default, the price is 65% of the lowest trading price over ten days.
- ONE44 Capital: Convertible after the 6th monthly anniversary at 65% of the lowest closing bid price over ten days.
- Prepayment Penalties: Both notes carry significant prepayment premiums ranging from 110% to 135% of the face amount plus accrued interest, depending on the timing of prepayment within the first 180 days.
- Default Provisions: Upon default, interest rates accelerate to 24% per annum. Failure to issue shares upon conversion triggers penalties of $250 per day (increasing to $500 per day after day 10).
- Ownership Caps: Both investors are restricted from converting if it would result in beneficial ownership exceeding 4.99% of outstanding shares.
Outlook, Risks, and Contingencies
Management intends to use the net proceeds ($188,000 total) for general working capital. The filing highlights several risks and contingencies:
- Dilution Risk: The low conversion prices and floating rates (65% of market price) create significant potential for shareholder dilution.
- Liquidity and Default Risk: The high prepayment premiums and default interest rates (24%) indicate high-cost financing. The company covenants not to dispose of assets in a way that renders it a "shell company."
- Legal Contingencies: The company is obligated to pay $5,500 in legal fees to ONE44 Capital, in addition to the $5,500 already paid to GS Capital.
Investor Verification Checklist
- Verify the current trading price of Propanc Biopharma common stock to assess immediate dilution impact under the GS Capital fixed price ($0.0028) and ONE44 floating price (65% of market).
- Confirm the company's current cash position to determine if it can meet the $11,000 in legal fees and future interest obligations without further dilution.
- Review the total outstanding share count to calculate the maximum number of shares issuable upon full conversion of both notes.
- Check for any existing defaults or prior convertible notes that may have similar prepayment or conversion terms.